Effect of Improved pET Plasmids on Protein Expression Yield and Basal Expression

Abstract

High-yield recombinant protein expression is a critical requirement in biopharmaceutical development. The pET vector family is among the most widely used systems for protein production in Escherichia coli. Shilling et al. (2020) reported that insertion of a GAGA sequence within the T7lac promoter region of pET28a enhanced protein expression and suggested broad applicability across the pET plasmid family [1]. In this study, the GAGA sequence was introduced into pET16b and pET11a plasmids, and the expression performance of the original and modified vectors was evaluated using two recombinant proteins in BL21(DE3) and BL21(DE3) pLysS cells. The modified plasmids produced variable protein yield, depending on the vector–protein combination. However, elevated basal (leaky) expression was observed in BL21(DE3) cells carrying the modified plasmids. This undesired effect was eliminated in BL21(DE3) pLysS cells. These results indicate that the impact of GAGA modification is dependent on the plasmid backbone, target protein, and host strain. While the modification can improve expression yields, we cannot say it is universally beneficial across all pET-based expression systems.

Keywords

• Recombinant Protein Expression
• Biopharmaceutical Production
• pET Plasmids

Supporting Institution

This project is partially supported by The Scientific and Technological Research Council of Türkiye (TÜBİTAK) project for HTS (Project no: 124S204).

Ethical Statement

Ethical approval was not required for this study because no human participants, human samples, animal subjects, or identifiable personal data were involved.

Thanks

The authors would like to acknowledge the Biotechnology and Bioengineering Research and Application Centre (BIYOMER) at Izmir Institute of Technology for SDS-PAGE gel imaging.

References

1. [1]. Shilling, PJ, Mirzadeh, K, Cumming, AJ, Widesheim, M, Köck, Z, Daley, DO. 2020. Improved designs for pET expression plasmids increase protein production yield in Escherichia coli. Communications Biology; 3(1). doi: 10.1038/S42003-020-0939-8.
2. [2]. Chander, D, Koul, D, Tickoo, A, Chaubey, A. 2025. Advancing recombinant protein production by bacteria: strategies and challenges in heterologous systems. Current Research in Biotechnology; 10: 100342. doi: 10.1016/J.CRBIOT.2025.100342.
3. [3]. Rosano, GL, Morales, ES, Ceccarelli, EA. 2019. New tools for recombinant protein production in Escherichia coli: A 5‐year update. Protein Science; 28(8): 1412. doi: 10.1002/PRO.3668.
4. [4]. Studier, FW. 1991. Use of bacteriophage T7 lysozyme to improve an inducible T7 expression system. Journal of Molecular Biology; 219(1): 37–44. doi: 10.1016/0022-2836(91)90855-Z.
5. [5]. Rosenberg, AH, Lade, BN, Dao-shan, C, Lin, SW, Dunn, JJ, Studier, FW. 1987. Vectors for selective expression of cloned DNAs by T7 RNA polymerase. Gene; 56(1): 25–135. doi: 10.1016/0378-1119(87)90165-X.
6. [6]. Studier, FW, Rosenberg, AH, Dunn, JJ, Dubendorff, JW. 1990. Use of T7 RNA polymerase to direct expression of cloned genes. Methods in Enzymology; 185(C): 60–89. doi: 10.1016/0076-6879(90)85008-C.
7. [7]. Dubendorf, JW, Studier, FW. 1991. Controlling basal expression in an inducible T7 expression system by blocking the target T7 promoter with lac repressor. Journal of Molecular Biology; 219(1): 45–59. doi: 10.1016/0022-2836(91)90856-2.
8. [8]. Lopez, PJ, Guillerez, J, Sousa, R, Dreyfus, M. 1997. The low processivity of T7 RNA polymerase over the initially transcribed sequence can limit productive initiation in vivo. Journal of Molecular Biology; 269(1): 41–51. doi: 10.1006/jmbi.1997.1039.

9. [9]. Adami, G, Rossini, M, Viapiana, O. 2025. Teriparatide in the Prevention and Treatment of Osteoporosis: an Update. Clinical & Translational Metabolism; 23(1): 15. doi: 10.1007/S40259-019-00386-X
10. [10]. Kovács, P, Schäfer, T, Háda, V, Hevér, H, Klingelhöfer, S, Nebel, M, Stadie, T, Kiss, R, Urbányi, Z. 2019. Comparative Physicochemical and Biological Characterisation of the Similar Biological Medicinal Product Teriparatide and Its Reference Medicinal Product. BioDrugs; 34(1): 65. doi: 10.1007/S40259-019-00386-X
11. [11]. Summers, BJ, Digianantonio, KM, Smaga, SS, Huang, PT, Zhou, K, Gerber, EE, Wang, W, Xiong, Y. 2019. Modular HIV-1 Capsid Assemblies Reveal Diverse Host-Capsid Recognition Mechanisms. Cell Host & Microbe; 26(2): 203. doi: 10.1016/J.CHOM.2019.07.007
12. [12]. Sahani, RL, Diana-Rivero, R, Vernekar, SKV, Wang, L, Du, H, Zhang, H, Castaner, AE, Casey, MC, Kirby, KA, Tedbury, PR, Xie, J, Sarafianos, SG, Wang, Z. 2021. Design, Synthesis and Characterization of HIV-1 CA-Targeting Small Molecules: Conformational Restriction of PF74. Viruses; 13(3): 479. doi: 10.3390/V13030479
13. [13]. Zhang, DW, Xu, XS, Zhou, R, Fu, Z. 2023. Modulation of HIV-1 capsid multimerization by sennoside A and sennoside B via interaction with the NTD/CTD interface in capsid hexamer. Frontiers in Microbiology; 14: 1270258. doi: 10.3389/FMICB.2023.1270258/TEXT
14. [14]. Pornillos, O., Ganser-Pornillos, B. K., Banumathi, S., Hua, Y., & Yeager, M. 2010. Disulfide bond stabilization of the hexameric capsomer of human immunodeficiency virus. Journal of Molecular Biology, 401(5): 985. doi: 10.1016/J.JMB.2010.06.042
15. [15]. Liu, H, Naismith, JH. 2008. An efficient one-step site-directed deletion, insertion, single and multiple-site plasmid mutagenesis protocol. BMC Biotechnology; 8: 91. doi: 10.1186/1472-6750-8-91.
16. [16]. Arkca, İ. 2024. Production of teriparatide, a biotechnological drug, with a novel method. Master’s thesis, Izmir Institute of Technology.
17. [17]. Zhang, X, Studier, FW. 1997. Mechanism of inhibition of bacteriophage T7 RNA polymerase by T7 lysozyme. Journal of Molecular Biology; 269(1): 10–27. doi: 10.1006/JMBI.1997.1016.
18. [18]. Agrawal, S, Padmaswari, M, Stokes, A, Maxenberger, D, Reese, M, Khalil, A, Nelson, C. 2024. Optimizing Recombinant Cas9 Expression: Insights from E. coli BL21(DE3) Strains for Enhanced Protein Purification and Genome Editing. Biomedicines; 12(6): 1226. doi: 10.3390/BIOMEDICINES12061226.
19. [19]. Rosano, GL, Ceccarelli, EA. 2014. Recombinant protein expression in Escherichia coli: advances and challenges. Frontiers in Microbiology; 5(APR): 172. doi: 10.3389/FMICB.2014.00172.
20. [20]. Studier, FW. 2005. Protein production by auto-induction in high density shaking cultures. Protein Expression and Purification; 41(1): 207–234. doi: 10.1016/J.PEP.2005.01.016.
21. [21]. Miroux, B, Walker, JE. 1996. Over-production of proteins in Escherichia coli: Mutant hosts that allow synthesis of some membrane proteins and globular proteins at high levels. Journal of Molecular Biology; 260(3): 289–298. doi: 10.1006/JMBI.1996.0399.
22. [22]. Saida, F, Uzan, M, Odaert, B, Bontems, F. 2006. Expression of highly toxic genes in E. coli: special strategies and genetic tools. Current Protein & Peptide Science; 7(1): 47–56. doi: 10.2174/138920306775474095.
23. [23]. Guzman, LM, Belin, D, Carson, MJ, Beckwith, J. 1995. Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAD promoter. Journal of Bacteriology; 177(14): 4121. doi: 10.1128/JB.177.14.4121-4130.1995.
24. [24]. Pan, SH, Malcolm, BA. 2000. Reduced background expression and improved plasmid stability with pET vectors in BL21 (DE3). Biotechniques; 29(6): 1234–1238. doi: 10.2144/00296ST03.